According to The Fly, clarus analyst Noel Atkinson maintained a Buy rating on CRH Medical Corporation (CRHM) on November 2. The company’s shares opened today at $3.05.
Atkinson wrote:
“We have moderated our Q4 deal outlook to US$8MM of spending from US$10MM previously to reflect the incremental activity in Q3. CRH also bought back another ~190k shares in Q3 for a total of 580k shares year-to-date.”
Atkinson has an average return of 17.0% when recommending CRH Medical Corporation.
According to TipRanks.com, Atkinson is ranked #64 out of 4900 analysts.
Currently, the analyst consensus on CRH Medical Corporation is a Strong Buy with an average price target of $3.50.
See today’s analyst top recommended stocks >>
CRH Medical Corporation’s market cap is currently $233.3M and has a P/E ratio of 28.43. The company has a Price to Book ratio of 3.28.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CRH Medical Corp. engages in the provision of gastroenterologists with innovative services and products for the treatment of gastrointestinal diseases. It offers CRH O’Regan System, which focuses on physician education, patient outcomes, and patient awareness. The company was founded in 2000 and is headquartered in Vancouver, Canada.
